Compare BridgeBio Pharma Inc (BBIO) vs VanEck Semiconductor ETF (SMH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs VanEck Semiconductor ETF — how do they compare? BridgeBio Pharma Inc trades at $84.71 (market cap $16.46B), while VanEck Semiconductor ETF trades at $607.5. Which is the better fit depends on your goals.
| BBIO | SMH | |
|---|---|---|
Market Cap | $16.46B | — |
Sector | Health | — |
52-Week High | $90.17 | $668.91 |
52-Week Low | $44.81 | $283.95 |
Enterprise Value | $18.02B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
SMH (VanEck Semiconductor ETF) trades at $585.62, down 4.22% over 24 hours amid a sector-wide sell-off. Technical indicators show a bearish trend with support at $579 and resistance at $589. Recent news highlights strong 2026 performance but notes high expectations and recent volatility in semiconductor stocks.
The ETF's outlook is clouded by near-term volatility, though long-term AI-driven demand for semiconductors remains a tailwind. Risks include sector concentration and macroeconomic pressures, but diversification within the chip industry offers a balanced exposure for investors seeking growth in technology infrastructure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About VanEck Semiconductor ETF
The fund normally invests at least 80% of its total assets in securities that comprise the target index. The index includes common stocks and depositary receipts of US exchange-listed companies in the semiconductor industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a US exchange. The fund is non-diversified.
Read more on SMH →
